Objectives: The aim of the study was to determine the interplay between the plasmid-mediated qepA2 gene and multiple chromosomally mediated fluoroquinolone resistance determinants in the development of fluoroquinolone resistance in Escherichia coli and its influence on bacterial fitness.
Introduction
Resistance to fluoroquinolones in Enterobacteriaceae mainly involves mutations in chromosomal genes encoding DNA gyrase and topoisomerase IV and decreased accumulation of fluoroquinolones due to changes in permeability. 1 Three different types of plasmid-mediated quinolone resistance (PMQR) or transferable mechanism of quinolone resistance have been described in Gram-negative microorganisms: Qnr proteins, an acetyltransferase [AAC(6 ′ )-Ib-cr] and efflux pumps (QepA and OqxAB). 2 The QepA determinant was described in Escherichia coli clinical isolates from Japan and Belgium in 2007. The qepA1 gene encodes an efflux pump protein [belonging to the major facilitator superfamily (MFS)] and confers decreased susceptibility to hydrophilic fluoroquinolones. 3, 4 In 2008, a new variant of this determinant, QepA2, was reported in France. 5 The aim of this study was to investigate the effect of the qepA2 gene and chromosomally mediated quinolone resistance mechanisms on quinolone susceptibility and biological cost. To evaluate this interplay, we constructed a collection of 21 isogenic E. coli strains carrying combinations of four chromosomally mediated quinolone resistance mechanisms that produced and did not produce QepA2 proteins.
Materials and methods

Bacterial strains and cloning assays
A set of 10 isogenic strains derived from E. coli ATCC 25922 (wild-type, WT) and harbouring Ser83Leu mutation and/or Asp87Asn mutation in GyrA and/or Ser80Arg mutation in ParC and/or a marR gene deletion 6 were used as background strains for combination with the qepA2 gene ( Table 1) .
E. coli BicA was used for qepA2 gene amplification. 5 The qepA2 gene, including the promoter sequences, was amplified using primers PreQepA2 (5 ′ -ggaagatcttccGGTCGATGTTTGATGTTATGGAG-3 ′ ) and PostQepA2 (5 ′ -ggaagatcttccAGAGCCGCCTGAGGCCATGCGAC-3 ′ ) and cloned into the pBK-CMV vector (underlined nucleotides correspond to the BglII site). This construct was electroporated into the 10 isogenic strains (Table 1) .
Antimicrobial susceptibility testing
Antimicrobial susceptibility was determined by microdilution according to CLSI guidelines. 7 The quinolones used were nalidixic acid, ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin and ofloxacin (Sigma -Aldrich, Madrid, Spain). Mutant prevention concentrations (MPCs) of ciprofloxacin and levofloxacin were determined as previously described. 8 Growth competition assays E. coli ATCC 25922 DlacZ was used as the standard strain against mutants constructed in the growth competition assays. 6 This strain was also tested against its parent, showing that the DlacZ mutation was neutral. Isogenic strains with qepA2 were tested against E. coli ATCC 25922 DlacZ pBK-CMV. Each competition was tested in at least six independent experiments (Table 1) . Growth competition assays were performed as described previously. 6 Relative fitness was calculated as the ratio of the log 10 cfu density of any strain harbouring some quinolone resistance mechanism to that of the control strain. 6, 9 Statistical significance of difference in fitness relative to the WT was measured using Student's t-test (two-tailed P, 0.05).
Results and discussion
The interplay between chromosomally mediated quinolone resistance and qnr genes in susceptibility to fluoroquinolones and bacterial fitness has recently been described. 6 However, the effect of the combination of other PMQR genes, such as qepA, with chromosomally mediated mechanisms is unknown. In the present study, a set of 21 isogenic E. coli strains was used to evaluate the relationship between chromosomally encoded fluoroquinolone resistance mutations and qepA2, drug susceptibility and bacterial fitness.
For microdilution results, the margin of error of MIC values was +1 half-doubling step, so that any change of at least two dilutions was considered significant. The presence of the qepA2 gene increased ciprofloxacin and norfloxacin (hydrophilic fluoroquinolones) MICs for all E. coli genotypes (Table 1) . In any combination, the ciprofloxacin MIC for strains harbouring the qepA2 gene increased 4-to 8-fold compared with strains without the qepA2 gene. The additional presence of qepA2 increased the norfloxacin MIC 4-to 16-fold. The MICs of the more hydrophobic quinolones evaluated were not significantly modified (Table S1 , available as Supplementary data at JAC Online). Together, a combination of the qepA2 gene plus two to three chromosomal quinolone resistance mechanisms was enough to modify the clinical category for hydrophilic fluoroquinolones, supporting the idea that the PMQR determinants have a relevant role in producing clinical resistance to quinolones. 6 EUCAST breakpoints are more restrictive than those defined by CLSI, including those for fluoroquinolones in Enterobacteriaceae. 7, 10 We observed frequent discrepancies between CLSI and EUCAST in strains containing the qepA2 gene combined with gyrA and/or parC modifications. These discrepancies were observed in 20% (10% susceptible/intermediate plus 10% intermediate/resistant) and 50% (40% susceptible/resistant plus 10% intermediate/resistant) of the full collection for ciprofloxacin and norfloxacin, respectively.
Taking EUCAST criteria into account, the epidemiological cut-off for ciprofloxacin in E. coli is established as 0.032 mg/L (www. eucast.org), which is considered to correspond to strains without known quinolone resistance mechanisms. 10 Herein, we showed evidence of the existence of strains carrying the qepA2 gene (EC60) or a deletion of the marR gene (EC01) 6 whose ciprofloxacin MICs were lower than the epidemiological cut-off (Table 1) , making it necessary to revise this epidemiological cut-off.
MPC levels were evaluated in three isogenic pairs harbouring one or two resistance mechanisms with or without qepA2 (EC60, EC62, EC64 compared with WT, EC02, EC04) ( Table 1) . 6 Ciprofloxacin MIC values ranged between 0.016 and 1 mg/L. Ciprofloxacin MPC values for strains harbouring the qepA2 gene were 4-to 16-fold (4 -128 mg/L) higher than for strains without qepA2 and, in most cases, greatly exceeded breakpoint concentrations for resistance according to CLSI and EUCAST criteria and the C max reached for this quinolone (Table S2) . 7, 10, 11 In growth competition assays, the qepA2 gene alone had no effect on growth fitness. In general, this PMQR gene in combination with mutations in gyrA or parC had a moderate fitness cost ( Figure S1 ). Unexpectedly, the deletion in the marR gene compensated for the fitness cost associated with QepA2. Strains carrying qepA2 and a deletion in the marR gene compensated for the fitness values, which ranged between 1.05 and 1.23 (Table 1 and Figure S1 ). The mechanism that caused this phenomenon is unknown; although, in accordance with previous data, certain chromosomal mutations could modify the fitness cost associated with PMQR. 12 Analysis of the promoter regions of qepA2 using the BPROM informatics tool (www.softberry.com) found a cpxR binding site, but we did not find any marR boxes that might explain the interaction between marR and QepA2.
Comparison of EC64 versus EC65 and EC68 versus EC69 showed that the presence of a deletion of the marR gene increased the MIC of ciprofloxacin 2-to 4-fold. In both cases, a 23% increase in bacterial fitness was also observed (Table 1) . At least in vitro, adding a single resistance mechanism may significantly modify bacterial fitness ( 20%) and simultaneously increase MICs. Accordingly, particular combinations of resistance mechanisms (e.g. QepA2 and DmarR) could be conserved in the absence of antimicrobial pressure, because they improve the relative fitness of the mutant strain and reduce drug susceptibility according to recent literature. 6, 9 Altogether, these results contrast with the central dogma of evolution, which states that resistance mechanisms confer a fitness cost and constitute an adaptive disadvantage in the absence of antimicrobials. Thus, the development of increasing rates of fluoroquinolone resistance could occur even in the absence of these drugs. Accordingly, strategies designed to reduce antimicrobial resistance rates should take the bacterial 
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